secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARTELO BIOSCIENCES, INC. (ARTL)
CIK:        0001621221
Form:       8-K
Filed at:   2025-07-11T23:59:59+00:00
Accession:  0001640334-25-001184
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Artelo Biosciences completes 1-for-6 reverse split; cash falls to $2.1M with negative working capital
--------------------------------------------------------------------------------

- 1-for-6 reverse split effective June 13, 2025, reducing outstanding shares from 3,280,000 to ~546,667.
- Authorized common shares cut from 50M to 8,333,333; preferred authorized reduced from 416,667 to 69,444.
- Preliminary June 30, 2025 cash & equivalents ~$2.1M; working capital expected between -$1.2M and -$1.5M.
- Company restates substantial doubt about going concern and continues to report recurring operating losses.
- FY2024 net loss $9.8M (vs $9.3M in FY2023); accumulated deficit reached $50.1M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621221/000164033425001184/0001640334-25-001184-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621221/000164033425001184/artl_8k.htm
  HTML page:      https://secwatch.observer/filing/0001640334-25-001184

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer